ALFA Finder| Revenue growth | FY26 standalone revenue down 8.64% to ₹1,704cr. |
|---|---|
| Margins | EBITDA margin improved from 18.98% to 19.81%. |
| Order book | Pending court order for 15cr litre additional allocation. |
| Demand visibility | Strong visibility from 20% to 21% blending mandate increase. |
| Management confidence | Confident in achieving 40-55cr litre ethanol targets for FY27. |
Growth
FY26 standalone revenue dipped 8.64% YoY; console revenue dropped 7% to ₹1,813cr. PAT fell from ₹140cr to ₹80.26cr due to higher depreciation/finance costs.
Outlook
Targeting 55cr litres ethanol sales in FY27. Expanding CBG to 10 plants. Setting up 10cr litre SAF plant in Andhra Pradesh.
Risks
Regulatory policy flip-flops, OMC tender allocation methodology disputes, and Middle Eastern crisis impacting crude prices/retail expansion.
Earnings Call filed with NSE, NSE: TRUALT. Summary written with AI assistance from the document.
TruAlt Bioenergy Ltd: key numbers
- Share price
- ₹350.00
- Market cap
- ₹3,001 Cr
- Revenue (annual)
- ₹1,728 Cr
- Net profit (annual)
- ₹95.95 Cr
- P/E (TTM)
- 13.6×Sector 29.0×
- Promoter holding
- 71.38%+0.83% QoQ
- FII holding
- 0.62%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from TruAlt Bioenergy Ltd
All →TruAlt Bioenergy Other Announcement
TruAlt Bioenergy filed Crisil's monitoring agency report for the quarter ended 30 September 2026 on its Rs 750 crore IPO proceeds. The report notes no deviation from the IPO objects.
TruAlt Bioenergy Earnings Call Transcript: Key Takeaways
TruAlt reported massive 606% YoY revenue growth, turning profitable despite raw material price surges. Management is pivoting from ethanol to high-margin CBG to insulate from feedstock volatility.
TruAlt Bioenergy Investor Presentation: Key Takeaways
Q2 FY27 consolidated total income ₹823.74 Cr, PAT ₹34.99 Cr, EBITDA margin 12.47%. H1 PAT ₹94.27 Cr, EBITDA ₹233.92 Cr (16.27% margin). Strategy: integrated bioenergy across ethanol, CBG, SAF, retail.
TruAlt Bioenergy Results Update
TruAlt Bioenergy reported H1 FY27 revenue of ₹1,437.98 crore, EBITDA of ₹233.92 crore and PAT of ₹94.27 crore via press release. Results reverse last year's H1 loss.
TruAlt Bioenergy Q2 FY27 Results: Turns Profitable, Net Profit ₹35 Cr
TruAlt Bioenergy Ltd reported revenue from operations of ₹811.1 Cr (+605.9% YoY) and net profit of ₹35 Cr for Q2 FY27.
- Key figure
- Net profit ₹35 Cr
TruAlt Bioenergy Management Change
Mr. Monu Kumar resigned as Company Secretary and Compliance Officer of TruAlt Bioenergy Limited, effective October 16, 2026, due to personal reasons.